ArticleResearch and reports in urology2026
Use of Methenamine Hippurate in an Ageing Population: National Prescription Trends from Norway (2004-2020).
Article in Research and reports in urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To describe national trends in methenamine hippurate prescribing in Norway, including variations by age and sex. Methods: Data were extracted from the Norwegian Prescription Database for 2004-2020. Methenamine hippurate was identified using ATC code J01XX05. All prescriptions were included; no exclusion criteria were applied. Outcomes included number of users, prevalence per 1000 persons, and distribution by age and sex. Analyses were descriptive. Results: From 2004 to 2020, use of methenamine hippurate increased steadily, with an average annual rise of 5.3%, reaching 35,134 unique users in 2020. Overall prevalence increased from 3.8 to 6.5 per 1000 persons. Women accounted for most users throughout; female prescribing increased from 5.5 to 11.3 per 1000 persons, while male use rose modestly from 1.3 to 1.8 per 1000 persons. The proportion of male users declined from 18.8% to 13.8%. Use was strongly age dependent: individuals aged ≥80 years accounted for around 60% of users. In 2020, rates peaked among women aged >90 years (64.9 per 1000) versus 25.8 per 1000 among men of the same age. Marked regional variation was observed, with higher use in northern and rural regions. Conclusion: Methenamine hippurate use in Norway has increased substantially, driven mainly by rising use among older women. Although prescribed less frequently, use among men persists. This trend may reflect increased awareness of the burden of recurrent urinary tract infections and a shift towards non-antibiotic prophylaxis. Further research is needed to evaluate prescribing appropriateness, clinical effectiveness, and implications for antimicrobial stewardship.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.